Dnmt3a缺失增加JAK2-V617F阳性骨髓增殖性肿瘤的自我更新能力并导致对聚乙二醇干扰素α耐药
研究在JAK2-V617F阳性骨髓增殖性肿瘤(MPN)小鼠模型及患者造血祖细胞中探讨DNMT3A缺失是否改变JAK2-V617F长期造血干细胞功能并导致对聚乙二醇干扰素α(pegIFN-α)耐药。单突变VF小鼠长期pegIFN-α治疗使血参数正常化并减少脾大和JAK2-V617F嵌合率,而VF;Dnmt3aΔ/Δ小鼠脾大加重且JAK2-V617F嵌合率未下降。VF;Dnmt3aΔ/Δ的长期造血干细胞DNA损伤积累减少、不易退出休眠,且IFN-α诱导的炎症通路上调更强。pegIFN-α联合5-氮杂胞苷仅部分克服VF;DmΔ/Δ小鼠的耐药,但强烈降低单突变VF小鼠的JAK2突变等位基因负荷。
要点
- VF;Dnmt3aΔ/Δ小鼠接受pegIFN-α后脾大加重,JAK2-V617F嵌合率未下降。
- VF;Dnmt3aΔ/Δ长期造血干细胞DNA损伤积累减少且不易退出休眠。
- JAK2-V617F合并DNMT3A突变患者祖细胞在IFN-α暴露后JAK2-V617F阳性集落百分比增加。
核心结论
- DNMT3A缺失导致JAK2-V617F长期造血干细胞功能改变,赋予对pegIFN-α治疗的耐药性。
- pegIFN-α联合5-氮杂胞苷仅部分克服VF;DmΔ/Δ小鼠的耐药。
研究设计与样本
- 研究采用MPN小鼠模型及MPN患者造血祖细胞,比较JAK2-V617F单突变(VF)与JAK2-V617F合并Dnmt3a缺失(VF;DmΔ/Δ)对pegIFN-α的反应。
- 小鼠接受长期pegIFN-α治疗,评估血参数、脾大、JAK2-V617F嵌合率及长期造血干细胞功能。
- 对pegIFN-α治疗的VF;DmΔ/Δ小鼠骨髓进行二次和三次移植。
- 对MPN患者造血祖细胞进行液相培养,观察IFN-α暴露后JAK2-V617F阳性集落百分比。
- 在VF;DmΔ/Δ小鼠中测试pegIFN-α联合5-氮杂胞苷的疗效。
主要发现
- VF小鼠长期pegIFN-α治疗使血参数正常化,并减少脾大和JAK2-V617F嵌合率。
- VF;DmΔ/Δ小鼠接受pegIFN-α后脾大加重,且JAK2-V617F嵌合率未下降。
- 与VF小鼠相比,VF;DmΔ/Δ小鼠的长期造血干细胞在pegIFN-α治疗后DNA损伤积累减少且不易退出休眠。
- RNA测序显示IFN-α在VF;DmΔ/Δ小鼠长期造血干细胞中诱导的炎症通路上调强于VF小鼠,表明耐药并非源于IFN-α信号传导失败。
- pegIFN-α治疗的VF;DmΔ/Δ小鼠骨髓移植后在二次和三次受者中产生更具侵袭性的疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pegylated interferon alfa (pegIFN-α) can induce molecular remissions in patients with JAK2-V617F-positive myeloproliferative neoplasms (MPNs) by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal, such as DNMT3A, have been reported to have poorer responses to pegIFN-α. We investigated whether DNMT3A loss leads to alterations in JAK2-V617F LT-HSC functions conferring resistance to pegIFN-α treatment in a mouse model of MPN and in hematopoietic progenitors from patients with MPN. Long-term treatment with pegIFN-α normalized blood parameters and reduced splenomegaly and JAK2-V617F chimerism in single-mutant JAK2-V617F (VF) mice. However, pegIFN-α in VF;Dnmt3aΔ/Δ (VF;DmΔ/Δ) mice worsened splenomegaly and failed to reduce JAK2-V617F chimerism. Furthermore, LT-HSCs from VF;DmΔ/Δ mice compared with VF were less prone to accumulate DNA damage and exit dormancy upon pegIFN-α treatment. RNA sequencing showed that IFN-α induced stronger upregulation of inflammatory pathways in LT-HSCs from VF;DmΔ/Δ than from VF mice, indicating that the resistance of VF;DmΔ/Δ LT-HSC was not due to failure in IFN-α signaling. Transplantations of bone marrow from pegIFN-α-treated VF;DmΔ/Δ mice gave rise to more aggressive disease in secondary and tertiary recipients. Liquid cultures of hematopoietic progenitors from patients with MPN with JAK2-V617F and DNMT3A mutation showed increased percentages of JAK2-V617F-positive colonies upon IFN-α exposure, whereas in patients with JAK2-V617F alone, the percentages of JAK2-V617F-positive colonies decreased or remained unchanged. PegIFN-α combined with 5-azacytidine only partially overcame resistance in VF;DmΔ/Δ mice. However, this combination strongly decreased the JAK2-mutant allele burden in mice carrying VF mutation only, showing potential to inflict substantial damage preferentially to the JAK2-mutant clone.
引用
- Usart M, Stetka J, Luque Paz D, et al. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024. PMID: 38493481. doi:10.1182/blood.2023020270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。